Literature DB >> 1372637

Pristanic acid and phytanic acid in plasma from patients with peroxisomal disorders: stable isotope dilution analysis with electron capture negative ion mass fragmentography.

H J ten Brink1, F Stellaard, C M van den Heuvel, R M Kok, D S Schor, R J Wanders, C Jakobs.   

Abstract

A sensitive and selective stable isotope dilution method was developed for the accurate quantitation of pristanic acid and phytanic acid using electron capture negative ion mass fragmentography on pentafluorobenzyl derivatives. This technique allows detection of 1 pg of each compound and was applied to plasma from healthy controls and patients suffering from various peroxisomal disorders. The age-dependency of phytanic and pristanic acid levels in plasma from healthy controls was demonstrated. The involvement of peroxisomes in the beta-oxidation of pristanic acid was concluded from its accumulation in plasma from patients with peroxisomal deficiencies. Pristanic acid/phytanic acid ratios were markedly increased in bifunctional protein and/or 3-oxoacyl-CoA thiolase deficiency, indicating their role in the (differential) diagnosis of disorders of peroxisomal beta-oxidation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1372637

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  13 in total

1.  A new peroxisomal beta-oxidation disorder in twin neonates: defective oxidation of both cerotic and pristanic acids.

Authors:  E Christensen; S A Pedersen; H Leth; C Jakobs; R B Schutgens; R J Wanders
Journal:  J Inherit Metab Dis       Date:  1997-09       Impact factor: 4.982

2.  The segregation of glutaryl-CoA dehydrogenase deficiency and Refsum syndrome in a family.

Authors:  E Christensen; N J Brandt; T Rosenberg; K Bömers; C Jakobs
Journal:  J Inherit Metab Dis       Date:  1994       Impact factor: 4.982

3.  Phytanoyl-CoA hydroxylase is not only deficient in classical Refsum disease but also in rhizomelic chondrodysplasia punctata.

Authors:  G A Jansen; S J Mihalik; P A Watkins; H W Moser; C Jakobs; H S Heijmans; R J Wanders
Journal:  J Inherit Metab Dis       Date:  1997-07       Impact factor: 4.982

4.  Formation of 2,3-pristenic acid and 3-hydroxypristanic acid from pristanic acid in human liver.

Authors:  N M Verhoeven; D S Schor; G A Jansen; R M Kok; H J ten Brink; R J Wanders; C Jakobs
Journal:  J Inherit Metab Dis       Date:  1997-07       Impact factor: 4.982

5.  Standard Reference Material (SRM) 2378 fatty acids in frozen human serum. Certification of a clinical SRM based on endogenous supplementation of polyunsaturated fatty acids.

Authors:  Bruce A Benner; Michele M Schantz; Carissa D Powers; Rosemary L Schleicher; Johanna E Camara; Katherine E Sharpless; James H Yen; Lorna T Sniegoski
Journal:  Anal Bioanal Chem       Date:  2018-02-13       Impact factor: 4.142

6.  Peroxisomal disorders: concentrations of metabolites in cerebrospinal fluid compared with plasma.

Authors:  H J ten Brink; C M van den Heuvel; B T Poll-The; R J Wanders; C Jakobs
Journal:  J Inherit Metab Dis       Date:  1993       Impact factor: 4.982

7.  Pre- and postnatal diagnosis of peroxisomal disorders using stable-isotope dilution gas chromatography--mass spectrometry.

Authors:  N M Verhoeven; W Kulik; C M van den Heuvel; C Jakobs
Journal:  J Inherit Metab Dis       Date:  1995       Impact factor: 4.982

Review 8.  Biochemistry of peroxisomes in health and disease.

Authors:  I Singh
Journal:  Mol Cell Biochem       Date:  1997-02       Impact factor: 3.396

9.  Measurement of very long-chain fatty acids, phytanic and pristanic acid in plasma and cultured fibroblasts by gas chromatography.

Authors:  G Dacremont; G Cocquyt; G Vincent
Journal:  J Inherit Metab Dis       Date:  1995       Impact factor: 4.982

10.  Oxidation of pristanic acid in fibroblasts and its application to the diagnosis of peroxisomal beta-oxidation defects.

Authors:  B C Paton; P C Sharp; D I Crane; A Poulos
Journal:  J Clin Invest       Date:  1996-02-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.